Literature DB >> 16231029

Circulating adiponectin levels, body composition and obesity-related variables in Prader-Willi syndrome: comparison with obese subjects.

L Kennedy1, D C Bittel, N Kibiryeva, S P Kalra, R Torto, M G Butler.   

Abstract

BACKGROUND: People with obesity and/or the metabolic syndrome have an increased risk for developing diabetes and cardiovascular disease and may have low adiponectin levels. The obesity associated with Prader-Willi syndrome (PWS) would be expected to have similar complications. However, it was recently reported that, despite their adiposity, people with PWS have reduced visceral fat and are less likely to develop diabetes mellitus or the metabolic syndrome compared with people with simple obesity.
OBJECTIVE: To determine if plasma adiponectin levels and other variables relevant to diabetes and cardiovascular risk are different in a cohort of PWS subjects with known genetic subtypes compared with age-, sex- and weight-matched control subjects.
RESULTS: Fasting plasma glucose, C-peptide, triglycerides, leptin and cholesterol levels were similar in PWS and obese subjects. Our 20 PWS subjects (mean age = 27.7 years) had higher percent body fat (54.1 vs 48.5%) determined by DEXA measurements and lower percent lean mass (45.9 vs 51.5%) compared with 14 obese controls (mean age = 26.9 year). Plasma adiponectin levels were significantly higher in PWS (15.5 +/- 8.2 microg/ml) than in obese controls (7.5 +/- 2.7 microg/ml). A significant positive correlation was found with insulin sensitivity in PWS subjects (r = 0.75, P = 0.0003) but not in obese controls (r = 0.36, P = 0.20). DISCUSSION: Our study confirmed an earlier observation of higher adiponectin levels in PWS subjects and less insulin resistance proportionate to their obesity status than found in subjects with simple obesity. Furthermore, no differences were seen in PWS subjects with the chromosome 15 deletion or maternal disomy 15. The reported excessive visceral adiposity in subjects with simple obesity compared with PWS may be associated with decreased production and lower circulating levels of adiponectin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16231029      PMCID: PMC6704478          DOI: 10.1038/sj.ijo.0803115

Source DB:  PubMed          Journal:  Int J Obes (Lond)        ISSN: 0307-0565            Impact factor:   5.095


  26 in total

1.  Impairment of adipose tissue in Prader-Willi syndrome rescued by growth hormone treatment.

Authors:  T Cadoudal; M Buléon; C Sengenès; G Diene; F Desneulin; C Molinas; S Eddiry; F Conte-Auriol; D Daviaud; P G P Martin; A Bouloumié; J-P Salles; M Tauber; P Valet
Journal:  Int J Obes (Lond)       Date:  2014-01-10       Impact factor: 5.095

2.  Does segmental body composition differ in women with Prader-Willi syndrome compared to women with essential obesity?

Authors:  G Bedogni; G Grugni; G Tringali; N Marazzi; A Sartorio
Journal:  J Endocrinol Invest       Date:  2015-04-04       Impact factor: 4.256

Review 3.  Role of ghrelin in the pathophysiology of eating disorders: implications for pharmacotherapy.

Authors:  Sebastian Cardona Cano; Myrte Merkestein; Karolina P Skibicka; Suzanne L Dickson; Roger A H Adan
Journal:  CNS Drugs       Date:  2012-04-01       Impact factor: 5.749

4.  Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial.

Authors:  Shawn E McCandless; Jack A Yanovski; Jennifer Miller; Cary Fu; Lynne M Bird; Parisa Salehi; Christine L Chan; Diane Stafford; M Jennifer Abuzzahab; David Viskochil; Sarah E Barlow; Moris Angulo; Susan E Myers; Barbara Y Whitman; Dennis Styne; Elizabeth Roof; Elisabeth M Dykens; Ann O Scheimann; Jaret Malloy; Dongliang Zhuang; Kristin Taylor; Thomas E Hughes; Dennis D Kim; Merlin G Butler
Journal:  Diabetes Obes Metab       Date:  2017-07-13       Impact factor: 6.577

5.  The metabolic phenotype of Prader-Willi syndrome (PWS) in childhood: heightened insulin sensitivity relative to body mass index.

Authors:  Andrea M Haqq; Michael J Muehlbauer; Christopher B Newgard; Steven Grambow; Michael Freemark
Journal:  J Clin Endocrinol Metab       Date:  2010-10-20       Impact factor: 5.958

6.  Brain structural alterations in obese children with and without Prader-Willi Syndrome.

Authors:  Mingze Xu; Yi Zhang; Karen M von Deneen; Huaiqiu Zhu; Jia-Hong Gao
Journal:  Hum Brain Mapp       Date:  2017-05-23       Impact factor: 5.038

7.  Leptin levels among prepubertal children with Down syndrome compared with their siblings.

Authors:  Sheela N Magge; Kristen L O'Neill; Justine Shults; Virginia A Stallings; Nicolas Stettler
Journal:  J Pediatr       Date:  2007-10-24       Impact factor: 4.406

8.  A reduced-energy intake, well-balanced diet improves weight control in children with Prader-Willi syndrome.

Authors:  J L Miller; C H Lynn; J Shuster; D J Driscoll
Journal:  J Hum Nutr Diet       Date:  2012-10-18       Impact factor: 3.089

9.  Altered distribution of adiponectin isoforms in children with Prader-Willi syndrome (PWS): association with insulin sensitivity and circulating satiety peptide hormones.

Authors:  Andrea M Haqq; Michael Muehlbauer; Laura P Svetkey; Christopher B Newgard; Jonathan Q Purnell; Steven C Grambow; Michael S Freemark
Journal:  Clin Endocrinol (Oxf)       Date:  2007-07-30       Impact factor: 3.478

10.  Effects of metformin in children and adolescents with Prader-Willi syndrome and early-onset morbid obesity: a pilot study.

Authors:  Jennifer L Miller; Tiffany D Linville; Elisabeth M Dykens
Journal:  J Pediatr Endocrinol Metab       Date:  2014-01       Impact factor: 1.634

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.